A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
NiKang Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Pliant Therapeutics, Inc.
Eli Lilly and Company
Eli Lilly and Company
Compass Therapeutics
Eli Lilly and Company
Kivu Bioscience Inc.
Astellas Pharma Inc
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Plexium, Inc.
Deciphera Pharmaceuticals, LLC
Revolution Medicines, Inc.
USWM, LLC (dba US WorldMeds)
Conjupro Biotherapeutics, Inc.
Alterome Therapeutics, Inc.
IDEAYA Biosciences
Pfizer
Aptamer Sciences, Inc.
National Cancer Institute (NCI)
GlaxoSmithKline
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Institut Paoli-Calmettes
Orano Med LLC
Conjupro Biotherapeutics, Inc.
Mayo Clinic
Stanford University
Boehringer Ingelheim
Fred Hutchinson Cancer Center
Tomsk National Research Medical Center of the Russian Academy of Sciences
Ankyra Therapeutics, Inc
Daiichi Sankyo
ViroMissile, Inc.
Pfizer
IntoCell, Inc
Pfizer
Tizona Therapeutics, Inc
InSilico Medicine Hong Kong Limited
Clasp Therapeutics, Inc.
Genentech, Inc.
Werewolf Therapeutics, Inc.
MacroGenics
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Prelude Therapeutics